Progress on drug treatment of chronic obstructive pulmonary disease

CHEN Kai-yu; JIANG Li-ping; CHEN Sheng-xin

doi:10.3969/j.issn.1006-0111.2012.06.003

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Volume 30 Issue 6

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Practice and Service > 2012 > 30(6): 408-411

CHEN Kai-yu, JIANG Li-ping, CHEN Sheng-xin. Progress on drug treatment of chronic obstructive pulmonary disease[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(6): 408-411. doi: 10.3969/j.issn.1006-0111.2012.06.003

Citation:

CHEN Kai-yu, JIANG Li-ping, CHEN Sheng-xin. Progress on drug treatment of chronic obstructive pulmonary disease[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(6): 408-411. doi: 10.3969/j.issn.1006-0111.2012.06.003

Progress on drug treatment of chronic obstructive pulmonary disease

doi: 10.3969/j.issn.1006-0111.2012.06.003

School of Pharmacy, Second Military Medical University, Shanghai 200433, China

Received Date: 2012-03-02
Rev Recd Date: 2012-05-28

Abstract

Chronic obstructive pulmonary disease(COPD), the fourth leading cause of death in the world, represented an important public health challenge. Appropriate medicine therapy in COPD was used to reduce symptoms, the frequency and severity of exacerbations, and improve exercise tolerance and health status. Rational use of the drugs that have different mechanisms, different duration of action was a research focus of COPD. The progress of COPD drug during these years and the strategy of drug treatment were reviewed in this paper.
- chronic obstructive pulmonary disease,
- drug treatment,
- drug combination

References

[1]	GOLD Executive Committee.Guidelines:Global Strategy for the Diagnosis,Manage-ment,and Prevention of Chronic Obstructive Pulmonary Disease(Revised 2011) [DB/OL],(2011-01-21)[2012-03-18].http://www.goldcopd.org/.
[2]	World Health Organization.The World Health Report 2000-Health systems:improving performance[R/OL]. [2012-03-18]. http://www.who.int/whr/2000/en/index.html.
[3]	Zhong N, Wang C, Yao W, et al. Prevalence of chronic obstructive pulmonary disease in China:a large, population-based survey[J].Am J Respir Crit Care Med,2007,176:753.
[4]	Lopez AD, Murray CC. The global burden of disease, 1990~2020[J]. Nat Med,1998,4:1241.
[5]	Hogg JC,Chu F,Utokaparch S,et al.The nature of small-airway obstruction in chronic obstructive pulmonary disease[J].N Engl J Med,2004,350:2645.
[6]	Bestall JC,Paul EA,Garrod R,et al.Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease[J].Thorax,1999,54:581.
[7]	Rahman I.Oxidative stress in pathogenesis of chronic obstructive pulmonary disease:cellular and molecular mechanisms[J].Cell Biochem Biophys,2005,43:167.
[8]	中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2007修订版) [J].中华结核和呼吸杂志,2007,46:254.
[9]	Schols AM,Soeters PB,Dingemans AM,et al.Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation,Am Rev Respir Dis,1993,147:1151.
[10]	卫生部办公厅.慢性阻塞性肺疾病诊疗规范(2011年版)[EB/OL]. (2011-08-12)[2012-03-18].http://www.moh.gov.cn/publicfiles/business/htmlfiles/mohyzs/s3586/201108/52675.htm.
[11]	COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease,a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial[J]. Chest,1994,105:1411.
[12]	Van Schayck CP,Folgering H,Harbers H,et al.Effects of allergy and age on responses to salbutamol and ipratropium bromide in? moderate asthma and chronic bronchitis[J]. Thorax,1991,46:355.
[13]	Tashkin DP,Fabbri LM. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease:current and future agents[J]. Respir Res,2010,11:149.
[14]	Donohue JF,Fabbri C,Lotvall J,et al.Once-daily bronchodilators for chronic obstructive pulmonary disease:indacaterol versus tiotropium[J].Am J Respir Crit Care Med,2010,182:155.
[15]	Casaburi R,Mahler DA,Jones PW,et al.A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease[J].Eur Respir J,2002,19:217.
[16]	陈新谦,金有豫,汤光. 新编药物学[M]. 第17版.北京:人民卫生出版社,2011:446.
[17]	Calverley PM,Anderson JA,Celli B,et al.Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease[J].N Engl J Med,2007,356:775.
[18]	Szafranski W,Cukier A,Ramirez A,et al.Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease[J].Eur Respir J,2003,21:74.
[19]	Rabe KF.Update on roflumilast,a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease[J].Br J Pharmacol,2011,163:53.
[20]	Hansen NC,Skriver A,Brorsen-Riis L,et al.Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis[J].Respir Med,1994,88:531.
[21]	Zheng JP,Kang J,Huang SG,et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study):a randomised placebo-controlled study[J]. Lancet,2008,371,2013.
[22]	朱铮. COPD的药物治疗进展[J]. 临床肺科杂志,2011,16:585.
[23]	Jones PW,Harding G,Berry P,et al.Development and first validation of the COPD Assessment Test[J].Eur Respir J, 2009,34:648.
[24]	Hurst JR,Vestbo J,Anzueto A,et al.Susceptibility to exacerbation in chronic obstructive pulmonary disease[J].N Engl Med,2010,363:1128.
[25]	Anthonisen NR,Connett JE,Kiley JP,et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study[J]. JAMA,1994, 272:1497.
[26]	Berry MJ,Rejeski WJ,Adair NE,et al. Exercise rehabilitation and chronic obstructive pulmonary disease stage[J]. Am J Respir Crit Care Med,1999,160:1248.
[27]	Centers for Disease Control and Prevention. Prevention and control of seasonal influenza with vaccines:recommendations of the Advisory Committee on Immunization Practices(ACIP),2009[J]. MMWR Recomm Rep,2009,58(RR08):1.
[28]	Hurst JR, Wedzicha JA.The biology of a chronic obstructive pulmonary disease exacerbation[J]. Clin Chest Med,2007,28:525.
[29]	Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations[J]. Am J Respir Crit Care Med,2006,173:1114.
[30]	Hurst JR, Wedzicha JA. Management and prevention of chronic obstructive pulmonary disease exacerbations:a state of the art review[J]. BMC Med,2009,7:40.

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views(15023) PDF downloads(2648) Cited by()

Proportional views

Progress on drug treatment of chronic obstructive pulmonary disease

School of Pharmacy, Second Military Medical University, Shanghai 200433, China

Received Date: 2012-03-02

Rev Recd Date: 2012-05-28

Key words:

Abstract: Chronic obstructive pulmonary disease(COPD), the fourth leading cause of death in the world, represented an important public health challenge. Appropriate medicine therapy in COPD was used to reduce symptoms, the frequency and severity of exacerbations, and improve exercise tolerance and health status. Rational use of the drugs that have different mechanisms, different duration of action was a research focus of COPD. The progress of COPD drug during these years and the strategy of drug treatment were reviewed in this paper.

HTML

Reference (30)

[1]	GOLD Executive Committee.Guidelines:Global Strategy for the Diagnosis,Manage-ment,and Prevention of Chronic Obstructive Pulmonary Disease(Revised 2011) [DB/OL],(2011-01-21)[2012-03-18].http://www.goldcopd.org/.
[2]	World Health Organization.The World Health Report 2000-Health systems:improving performance[R/OL]. [2012-03-18]. http://www.who.int/whr/2000/en/index.html.
[3]	Zhong N, Wang C, Yao W, et al. Prevalence of chronic obstructive pulmonary disease in China:a large, population-based survey[J].Am J Respir Crit Care Med,2007,176:753.
[4]	Lopez AD, Murray CC. The global burden of disease, 1990~2020[J]. Nat Med,1998,4:1241.
[5]	Hogg JC,Chu F,Utokaparch S,et al.The nature of small-airway obstruction in chronic obstructive pulmonary disease[J].N Engl J Med,2004,350:2645.
[6]	Bestall JC,Paul EA,Garrod R,et al.Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease[J].Thorax,1999,54:581.
[7]	Rahman I.Oxidative stress in pathogenesis of chronic obstructive pulmonary disease:cellular and molecular mechanisms[J].Cell Biochem Biophys,2005,43:167.
[8]	中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2007修订版) [J].中华结核和呼吸杂志,2007,46:254.
[9]	Schols AM,Soeters PB,Dingemans AM,et al.Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation,Am Rev Respir Dis,1993,147:1151.
[10]	卫生部办公厅.慢性阻塞性肺疾病诊疗规范(2011年版)[EB/OL]. (2011-08-12)[2012-03-18].http://www.moh.gov.cn/publicfiles/business/htmlfiles/mohyzs/s3586/201108/52675.htm.
[11]	COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease,a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial[J]. Chest,1994,105:1411.
[12]	Van Schayck CP,Folgering H,Harbers H,et al.Effects of allergy and age on responses to salbutamol and ipratropium bromide in? moderate asthma and chronic bronchitis[J]. Thorax,1991,46:355.
[13]	Tashkin DP,Fabbri LM. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease:current and future agents[J]. Respir Res,2010,11:149.
[14]	Donohue JF,Fabbri C,Lotvall J,et al.Once-daily bronchodilators for chronic obstructive pulmonary disease:indacaterol versus tiotropium[J].Am J Respir Crit Care Med,2010,182:155.
[15]	Casaburi R,Mahler DA,Jones PW,et al.A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease[J].Eur Respir J,2002,19:217.
[16]	陈新谦,金有豫,汤光. 新编药物学[M]. 第17版.北京:人民卫生出版社,2011:446.
[17]	Calverley PM,Anderson JA,Celli B,et al.Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease[J].N Engl J Med,2007,356:775.
[18]	Szafranski W,Cukier A,Ramirez A,et al.Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease[J].Eur Respir J,2003,21:74.
[19]	Rabe KF.Update on roflumilast,a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease[J].Br J Pharmacol,2011,163:53.
[20]	Hansen NC,Skriver A,Brorsen-Riis L,et al.Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis[J].Respir Med,1994,88:531.
[21]	Zheng JP,Kang J,Huang SG,et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study):a randomised placebo-controlled study[J]. Lancet,2008,371,2013.
[22]	朱铮. COPD的药物治疗进展[J]. 临床肺科杂志,2011,16:585.
[23]	Jones PW,Harding G,Berry P,et al.Development and first validation of the COPD Assessment Test[J].Eur Respir J, 2009,34:648.
[24]	Hurst JR,Vestbo J,Anzueto A,et al.Susceptibility to exacerbation in chronic obstructive pulmonary disease[J].N Engl Med,2010,363:1128.
[25]	Anthonisen NR,Connett JE,Kiley JP,et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study[J]. JAMA,1994, 272:1497.
[26]	Berry MJ,Rejeski WJ,Adair NE,et al. Exercise rehabilitation and chronic obstructive pulmonary disease stage[J]. Am J Respir Crit Care Med,1999,160:1248.
[27]	Centers for Disease Control and Prevention. Prevention and control of seasonal influenza with vaccines:recommendations of the Advisory Committee on Immunization Practices(ACIP),2009[J]. MMWR Recomm Rep,2009,58(RR08):1.
[28]	Hurst JR, Wedzicha JA.The biology of a chronic obstructive pulmonary disease exacerbation[J]. Clin Chest Med,2007,28:525.
[29]	Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations[J]. Am J Respir Crit Care Med,2006,173:1114.
[30]	Hurst JR, Wedzicha JA. Management and prevention of chronic obstructive pulmonary disease exacerbations:a state of the art review[J]. BMC Med,2009,7:40.

Message Board

Progress on drug treatment of chronic obstructive pulmonary disease

doi: 10.3969/j.issn.1006-0111.2012.06.003

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views